Skip to content

Study · Not a test of the peptide alone · 2021

4 results

Preparation of Targeted Mitochondrion Nanoscale-Release Peptides and Their Efficiency on Eukaryotic Cells.

He Y, Quan Z, Zhang R, He B, Xu Y, Chen Z, Ren Y, Li K

Journal of biomedical nanotechnology1 Aug 2021Cited by 2 (Europe PMC)

PMID34544544 (opens in a new tab)DOI10.1166/jbn.2021.3141 (opens in a new tab)PepBankPUB-34544544
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Elamipretide (SS-31).

  1. 01LabNot a test of Elamipretide (SS-31) aloneIn vitro (cells)Efficacy outcome

    In 661W cells, SiO2@SS31 gave more sustained protection than free SS31 at 48 h in the MTT assay.

    In plain wordsIn cells, the nanoparticle form of SS31 protected cells for longer than plain SS31 at 48 hours.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseCell protection at 48 h, SiO2@SS31 versus SS31
    Study

    n: not reported in source

    661W cells
    Comparator
    SS31
    Outcome group
    Mitochondrial function · Whole body

    Source sentences

    Summary
    The MTT assay suggested that SiO₂@SS31 has sustained protection compared with SS31 in the 661W cells at 48 h.
    1 context sentence
    Summary · context
    We explored the protection of SiO₂@SS31 on the 661W cells after oxidative injury by H₂O₂.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

  2. 02LabNot a test of Elamipretide (SS-31) aloneIn vitro (cells)Pharmacokinetics

    In 661W cells, flow cytometry showed that SiO2@FITC-SS31 maintained a high level and lasted longer after 24 h.

    In plain wordsIn cells, the nanoparticle-carried SS31 stayed at a high level inside cells for longer after 24 hours.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseIntracellular retention of SiO2@FITC-SS31
    Study

    n: not reported in source

    661W cells
    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    Flow cytometry proved SiO₂@FITC-SS31 could maintain a high level and last longer after 24 h.
    1 context sentence
    Summary · context
    We explored the protection of SiO₂@SS31 on the 661W cells after oxidative injury by H₂O₂.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

  3. 03LabNot a test of Elamipretide (SS-31) aloneIn vitro (cell-free)Pharmacokinetics

    In deionized water and normal saline, SiO2@SS31 nanoparticles decomposed completely within 15 days and released SS31 peptide.

    In plain wordsIn lab tests, silica nanoparticles carrying SS31 broke down fully within 15 days and released the peptide in water and saline.

    Peptide
    Elamipretide (SS-31)
    Outcome
    Not applicableSS31 release from SiO2@SS31 in deionized water and saline
    Study

    n: not reported in source

    SiO2@SS31 nanoparticles in deionized water and normal saline
    Outcome group
    Pharmacokinetics · Pharmacology

    Measurements

    Time to complete decomposition
    15 days
    deionized water and normal saline

    Source sentences

    Summary
    Within 15 days, the SiO2@SS31 nanoparticles were completely decomposed and simultaneously released the SS31 peptide in deionized water and normal saline.
    1 context sentence
    Summary · context
    We explored the protection of SiO₂@SS31 on the 661W cells after oxidative injury by H₂O₂.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

  4. 04LabNot a test of Elamipretide (SS-31) aloneIn vitro (cell-free)Pharmacokinetics

    SiO2@SS31 released SS31 faster in simulated body fluid and serum than in water or saline.

    In plain wordsIn lab tests, the nanoparticles released SS31 faster in simulated body fluid and serum than in water or saline.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseSS31 release in simulated body fluid and serum
    Study

    n: not reported in source

    SiO2@SS31 nanoparticles in simulated body fluid and serum
    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    Within 15 days, the SiO2@SS31 nanoparticles were completely decomposed and simultaneously released the SS31 peptide in deionized water and normal saline. Nonetheless, the process was faster in simulated body fluid and serum.
    1 context sentence
    Summary · context
    We explored the protection of SiO₂@SS31 on the 661W cells after oxidative injury by H₂O₂.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.